Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

被引：81

作者：

Attard, G. ^{[1
,2
]}

Clark, J. ^{[1
]}

Ambroisine, L. ^{[3
]}

Mills, I. G. ^{[4
]}

Fisher, G. ^{[3
]}

Flohr, P. ^{[1
]}

Reid, A. ^{[1
,2
]}

Edwards, S. ^{[1
]}

Kovacs, G. ^{[5
]}

Berney, D. ^{[6
]}

Foster, C. ^{[7
]}

Massie, C. E. ^{[4
]}

Fletcher, A. ^{[1
]}

De Bono, J. S. ^{[1
,2
]}

Scardino, P. ^{[8
,9
]}

Cuzick, J. ^{[3
]}

Cooper, C. S. ^{[1
]}

机构：

[1] Male Urol Canc Res Ctr, Inst Canc Res, Sutton SM2 5NG, Surrey, England

[2] Royal Marsden NHS Trust Fdn Hosp, Sutton SM2 5PT, Surrey, England

[3] Univ London, St Bartholomews Med Sch, Wolfson Inst Prevent Med, Canc Res UK Ctr Epidemiol,Dept Math & Stat, London EC1M 6BQ, England

[4] Univ Cambridge, Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Dept Oncol,Urooncol Res Grp, Cambridge CB2 0RE, England

[5] Heidelberg Univ, Heidelberg Klinikum, D-69120 Heidelberg, Germany

[6] St Bartholomews Hosp, Orchid Tissue Lab, London EC1A 7BE, England

[7] Univ Liverpool, Royal Liverpool Univ Hosp, Dept Pathol, Liverpool L69 3GA, Merseyside, England

[8] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA

[9] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA

来源：

BRITISH JOURNAL OF CANCER | 2008年 / 99卷 / 02期

基金：

英国医学研究理事会;

关键词：

prostate cancer; ETV1; ACSL3; ACSL3 : ETV1 fusion;

D O I：

10.1038/sj.bjc.6604472

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P = 0.001), PSA level at diagnosis (P = < 0.0001) and clinical stage (P = 0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

引用

页码：314 / 320

页数：7

共 28 条

[1] Prostate cancer and the Will Rogers phenomenon [J].

Albertsen, PC ;

Hanley, JA ;

Barrows, GH ;

Penson, DF ;

Kowalczyk, PDH ;

Sanders, MM ;

Fine, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253

[2] Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer [J].

Attard, G. ;

Clark, J. ;

Ambroisine, L. ;

Fisher, G. ;

Kovacs, G. ;

Flohr, P. ;

Berney, D. ;

Foster, C. S. ;

Fletcher, A. ;

Gerald, W. L. ;

Moller, H. ;

Reuter, V. ;

De Bono, J. S. ;

Scardino, P. ;

Cuzick, J. ;

Cooper, C. S. .

ONCOGENE, 2008, 27 (03) :253-263

[3] Cell- and gene-specific regulation of primary target genes by the androgen receptor [J].

Bolton, Eric C. ;

So, Alex Y. ;

Chaivorapol, Christina ;

Haqq, Christopher M. ;

Li, Hao ;

Yamamoto, Keith R. .

GENES & DEVELOPMENT, 2007, 21 (16) :2005-2017

[4] Complex patterns of ETS gene alteration arise during cancer development in the human prostate [J].

Clark, J. ;

Attard, G. ;

Jhavar, S. ;

Flohr, P. ;

Reid, A. ;

De-Bono, J. ;

Eeles, R. ;

Scardino, P. ;

Cuzick, J. ;

Fisher, G. ;

Parker, M. D. ;

Foster, C. S. ;

Berney, D. ;

Kovacs, G. ;

Cooper, C. S. .

ONCOGENE, 2008, 27 (14) :1993-2003

[5] Diversity of TMPRSS2-ERG fusion transcripts in the human prostate [J].

Clark, J. ;

Merson, S. ;

Jhavar, S. ;

Flohr, P. ;

Edwards, S. ;

Foster, C. S. ;

Eeles, R. ;

Martin, F. L. ;

Phillips, D. H. ;

Crundwell, M. ;

Christmas, T. ;

Thompson, A. ;

Fisher, C. ;

Kovacs, G. ;

Cooper, C. S. .

ONCOGENE, 2007, 26 (18) :2667-2673

[6] Long-term outcome among men with conservatively treated localised prostate cancer [J].

Cuzick, J. ;

Fisher, G. ;

Kattan, M. W. ;

Berney, D. ;

Oliver, T. ;

Foster, C. S. ;

Moller, H. ;

Reuter, V. ;

Fearn, P. ;

Eastham, J. ;

Scardino, P. .

BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1186-1194

[7] TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort [J].

Demichelis, F. ;

Fall, K. ;

Perner, S. ;

Andren, O. ;

Schmidt, F. ;

Setlur, S. R. ;

Hoshida, Y. ;

Mosquera, J-M ;

Pawitan, Y. ;

Lee, C. ;

Adami, H-O ;

Mucci, L. A. ;

Kantoff, P. W. ;

Andersson, S-O ;

Chinnaiyan, A. M. ;

Johansson, J-E ;

Rubin, M. A. .

ONCOGENE, 2007, 26 (31) :4596-4599

[8]

Foster CS, 2000, PROSTATE, P4

[9] Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome [J].

Foster, CS ;

Falconer, A ;

Dodson, AR ;

Norman, AR ;

Dennis, N ;

Fletcher, A ;

Southgate, C ;

Dowe, A ;

Dearnaley, D ;

Jhavar, S ;

Eeles, R ;

Feber, A ;

Cooper, CS .

ONCOGENE, 2004, 23 (35) :5871-5879

[10] Cellular and molecular pathology of prostate cancer precursors [J].

Foster, CS ;

Bostwick, DG ;

Bonkhoff, H ;

Damber, JE ;

van der Kwast, T ;

Montironi, R ;

Sakr, WA .

SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2000, 34 :19-43

← 1 2 3 →